April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Longitudinal Variability Of Biomarkers for Dry Eye Disease - Implications for Clinical Trials
Author Affiliations & Notes
  • Benjamin D. Sullivan
    TearLab Corp, San Diego, California
  • Baris Sonmez
    School of Medicine, Ondokuz Mayis University, Samsun, Turkey
  • María F. de la Paz
    Centro de Oftalmologia Barraquer, Barcelona, Spain
  • Michael S. Berg
    TearLab Corp, San Diego, California
  • Michael A. Lemp
    Ophthalmology, Georgetown & George Washington Univ, Lake Wales, Florida
  • Footnotes
    Commercial Relationships  Benjamin D. Sullivan, TearLab, Corp. (I, E), TearLab, Corp., US7017394 (P); Baris Sonmez, None; María F. de la Paz, None; Michael S. Berg, TearLab, Corp. (I, E); Michael A. Lemp, TearLab, Corp. (I, C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3804. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benjamin D. Sullivan, Baris Sonmez, María F. de la Paz, Michael S. Berg, Michael A. Lemp; Longitudinal Variability Of Biomarkers for Dry Eye Disease - Implications for Clinical Trials. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3804.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The purpose of this study was to evaluate normative statistics of biomarkers for dry eye disease over time periods typical of clinical trials. An additional therapeutic arm continued to follow a subset of patients on Restasis therapy to determine the comparative efficacy of signs in measuring treatment effect.

Methods: : Bilateral tear film breakup time (TBUT), Schirmers, staining, meibomian gland grading, OSDI, and tear osmolarity were measured over three consecutive months. 52 subjects completed the study across two sites (n=16 mild/moderate, n=36 severe dry eye). 10 subjects were prescribed Restasis and signs were recorded for an additional three months. To compare variability, the average observed range (as defined by the difference of maximum and minimum values of the more severe eye across all three visits) was calculated as a percentage of the dynamic range for each marker.

Results: : Tear osmolarity (16.7±12.2%) was found to have significantly less variability over three months than TBUT (30.2±26.1%, p<0.001), Schirmers (30.6±26.5%, p<0.001), meibomain gland scoring (26.5±16.5%, p<0.001) and OSDI (24.8±18.4%, p<0.01). Across all subjects, there was no difference between osmolarity and corneal (12.6±15.3%, p<0.14) or conjunctival (15.4±17.9%, p<0.67) staining. However, the majority of subjects at one site (20/31) demonstrated zero staining, artificially lowering its average variability. Osmolarity variation was significantly less in mild patients (11±6%) than in severe patients (19±13%, p<0.03). For subjects enrolled in the therapeutic arm, the average pretreatment osmolarity was significantly reduced from 341±18 mOsms/L to 307±8 mOsms/L (p=0.000002), while OSDI was significantly reduced from 51±18 to 38±18 (p=0.04). None of the other signs demonstrated a significant change in response to treatment.

Conclusions: : The longitudinal variability of tear film osmolarity is significantly less than the other biomarkers of dry eye disease. Changes in osmolarity were paralleled by changes in symptoms during therapy.

Keywords: cornea: tears/tear film/dry eye • cornea: clinical science • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.